Site Map
- Home
- Our People
- Our Board
- Our Experts
- Ankush Taneja
- Ann-Marie Chapman
- Anne-Marie Barnes
- Catarina Neves
- Catherine Rycroft
- Catriona Crossan
- Chrissy Lowry
- Frank van Hees
- Inderpreet Khurana
- James Horscroft
- Jane Moorhouse
- Karl Patterson
- Linda Murphy
- Lisa Cox
- Marjolijn van Keep
- Matthew Madin-Warburton
- Matthew Woods
- Miranda Cooper
- Phil Morgan
- Renu Patel
- Richard Birnie
- Sallie Latimer
- Simon McNamara
- Suzette Matthijsse
- Yang Meng
- Our Team
- Our Services
- Our Clients
- Publications
- Demonstrating the Value of Drugs for Rare Diseases – 8 Common Challenges and How to Address Them Before They Arise
- The UK joining Project Orbis post-Brexit may mean compressed timelines and less data for health technology assessment submissions
- Navigating the assessment of CAR T-cell therapies: Stepping back to look forwards
- ‘Excel cannot complete this task’: Drawing parallels between UK Test and Trace and health economic models
- How the latest NICE methods consultation could impact your evidence generation strategy
- NICE Technical Engagement Process: Navigating the Latest Changes
- Accelerating access to new innovative treatments: Lessons from COVID-19
- Navigating the post-COVID landscape
- Five learnings manufacturers should take from the latest NICE guidance on survival modelling
- Connecting the dots: Harnessing real-world data in healthcare decision making
- When too early isn’t early enough: Scalable early-phase literature reviews to optimize reimbursement and maximize resources
- An introduction to planning for HTA for tumour-agnostic cancer drugs
- Heterogeneity & generalizability: The core difficulties in estimating the effectiveness of tumour-agnostic drugs in practice
- Our news & events
- Join Us
- Contact Us
- Our People
- Site Map
- Cookie Policy
- Privacy Policy
- Terms & Conditions
- Search Results
- Advanced Search
